Search and selection of guidelines (2) Appraisal of guidelines through the AGREE II tool (3) Assessment of the rate of utilization of a subset of guidance documents in clinical practice (4) Synthesis of recommendations and other information concerning tumor markers into summary tables (5) Assessment of correctness and completeness of the information summarized in the tables
Introduction e335
Methodology e336
Take-home messages

Users' instructions e340
Biliary cancer e341
Colorectal cancer e342
Esophageal cancer e344
Gastric cancer e345
Hepatocellular carcinoma e346
Pancreatic cancer e348
Detailed summary tables
Users' instructions e349
Biliary cancer e350
Colorectal cancer e352
Esophageal cancer e355
Gastric cancer e356
Hepatocellular carcinoma e357
Pancreatic cancer e359
Selected guidelines (by cancer site) e361
Introduction
Some studies have recently shown that the number of tumor markers (TMs) requested is considerably higher than expected based on cancer prevalence (1, 2) , and that many factors may contribute to overordering of laboratory tests (3) . These findings are in agreement with studies performed in case series showing that TMs are frequently requested inappropriately (4) . The high rate of overutilization is related to an increased risk of both overdiagnosis and false positive results, with significant repercussions both on individual patients and health care systems (5) .
The pathway of knowledge translation of TM research results to clinical practice has changed over the years. Until a couple of decades ago, primary studies were considered the major source of information for clinical practice; studies reporting promising results were frequently advocated to sustain the utilization of the marker. Over the last 2 decadesalso because of a progressive shrinkage of resources allotted to the health care sector -clinical practice guidelines (CPGs) have been more and more frequently considered the reference evidence to support clinical choices. However, it should be noted that the primary studies concerning TMs frequently lack design requirements needed to provide good-level evidence according to criteria set for therapeutic intervention trials. Randomization and blinding methods are applied in only few studies where a TM is used as a predictive marker to select patients for a given therapy. The majority of studies on TMs evaluate the diagnostic or prognostic information provided by the markers in a nonrandomized manner; in the case of determination of circulating tumor markers, whichever the result may be, it has no immediate impact on clinical decision-making. As a result, panels preparing CPGs typically lack high-level evidence on TMs according to standard requirements for intervention trials; they frequently either do not produce recommendations, or opt for formulating negative recommendations.
Nevertheless, in spite of either available negative recommendations or the absence of recommendations, TM overordering persists and tends to increase over time, demonstrating the poor adherence of clinicians to CPGs. Many barriers may prevent clinicians from following guideline recommendations, including discrepancies between promising results of primary studies and the cautious position of CPGs, and the frequent poor consistency between recommendations prepared by different CPGs on the same clinical question.
Diagnostic randomized controlled trials are still infrequently performed, and although the number of comparative diagnostic test accuracy studies is increasing, the vast majority of the available evidence comes from single test evaluation studies. The latter studies do not measure patient-relevant outcomes directly, and cannot be equated to pharmacological clinical trials due to intrinsic differences in both design and endpoints. Although a framework of "linked evidence" has been in place for years, which strives to use evidence on true positive, true negative, false positive and false negative test results to deduct therapeutic and other patient-relevant consequences of testing, the application of this framework has been shown to be challenging (6) . While awaiting the dis-tillation of higher quality evidence into comprehensive guidelines with possibly an application of the linked-evidence or related frameworks (7) , efforts should be made to improve the adherence to existing guidelines.
Harmonization of different CPGs is a current strategy to handle uncertainties or discrepancies between different CPGs in settings where the clinical questions are complex, e.g., screening programs or disease prevention campaigns. Studies on the harmonization of recommendations for circulating cancer biomarkers have not been published so far.
The aim of the present research project is to develop a tool to summarize the recommendations and supplementary information on circulating TMs offered by available CPGs on solid tumors. The tool is intended to provide all possible evidence-based choices concerning TMs for people facing a clinical question in which the use of a TM could be contemplated.
Diligence was adopted to develop the tool according to a structured and rigorous methodology in order to guarantee the accurate extraction of relevant information including recommendations from selected guidelines as well as the validity of the synthesis of information from different sources.
Recommendations and supplementary information extracted from CPGs were clustered and summarized applying 4 increasing levels of synthesis, summarizing and simplifying the information to make it explicit, verifiable, valid and reproducible. The first 2 levels of clustering and synthesis are available for consultation upon request. The last 2 levels of synthesis are reported in the present article. They are the Detailed Summary Tables and Take-Home Messages, which represent the levels of synthesis suitable for practical use. The Take-Home Messages are intended for use by health care providers in clinical practice with the goal of improving the appropriateness of TM use. The Detailed Summary Tables can be used by policy makers for potential adaptation to their own context and by educators to design teaching programs consistent with the available evidence.
The tabulation of the information has been structured by individual malignancies. Within each malignancy, we clustered the information according to a set of clinical questions established as being common to all malignancies. A parallel assessment of the quality of the included CPGs has been performed and the results are shown alongside the Take-Home Messages in order to inform the reader about the quality of the source (CPGs) from which the recommendations were distilled.
The purpose of this project was to provide an accurate and synthetic reproduction of the available evidence on the clinical use of circulating TMs. We endeavored to avoid any interpretation of the content of CPGs and used verbatim reporting of the original sentences whenever possible.
Likewise, the expert panel intentionally avoided expressing its own opinion in cases where different CPGs showed discrepant positions on a clinical question. Dissimilar recommendations of diverse CPGs may be due to different causes; in fact, CPG panels have to interpret the primary TM evidence in different local contexts with possibly dissimilar available resources or patient preferences. Our panel deemed that the complete presentation of clinical questions in which the consistency between guidelines seemed poor represents a strength of the present project for 2 reasons; firstly, it provides an inventory of all possible recommendations after the application of evidence synthesis frameworks; secondly, it should help identify areas in which primary studies are especially needed to answer clinical questions concerning TMs.
Methodology
Scope
CPGs are critical for translating evidence to application in medical decision-making. Trustworthy guidelines are based on a systematic review of the clinical evidence (1, 2) . The number of CPGs has grown considerably and their quality is often heterogeneous. The objective of the project was to provide an easy-to-use but complete synthesis of TM recommendations distilled from evidence-based CPGs. The ultimate aim was to improve the appropriate use of TMs in clinical practice.
For the synthesis document to be useful it had to have the following characteristics: − to be developed with sound and structured methodology − to include all recommendations and information on circulating biomarkers reported in CPGs on solid tumors − to synthesize recommendations and information in easy-touse tables at 2 decreasing levels of complexity − to be useful for the following target audience: (i) health care providers, (ii) policy makers for potential adaptation to specific settings, and (iii) staff developing educational material informed by available evidence.
Panel composition and project planning
The participating institutions and scientific societies suggested 74 delegates to be enrolled in the expert panel. The panel comprised a multidisciplinary group of medical oncologists, radiation oncologists, clinical pathologists, general practitioners, internists, gynecologists, urologists, and experts in evidence-based methodology.
The project was organized in work packages (WPs) with dedicated tasks and milestones: WP1 -Definition of the primary objectives of the project and management strategies WP2 -Search and selection of guidelines WP3 -Appraisal of guidelines through the AGREE II tool WP4 -Assessment of the rate of utilization of a subset of guidance documents in clinical practice WP5 -Synthesis into "Detailed Summary Tables" and "Take-Home Messages" regarding the recommended use of TMs WP6 -Assessment of the correctness and completeness of the information summarized in the summary tables by our expert panel (n=74) WP7 -External and independent verification of the correctness and completeness of the information summarized in the tables by an independent external committee (n=18). WP1 was jointly managed by the Steering Committee and the Scientific Committee of the project. The activities of WPs 2 to 6 were carried out by working groups composed of members of the expert panel, in which oncologists and other clinicians, laboratory staff, methodologists and other research staff participated (see p. e364-e367). WP7 was realized by the members of the Interregional Biomarkers Working Group, instituted by the Health Commission of the Italian Permanent Conference for Relations between State, Regions and the Autonomous Provinces of Trento and Bolzano.
Search and selection process
We performed a systematic search for CPGs in the following databases: PubMed, the National Guidelines Clearinghouse and the GIN library. The search for guidance documents included the following search terms, their synonyms, and associated MESH terms: "guideline OR recommendation OR consensus OR consensus development conference" AND "neoplasms OR carcinoma OR cancer OR tumor". We included guidance documents published from January 2009 to July 2015 in English or Italian. The search identified a total of 8,266 citations. In addition to searching bibliographic databases, we searched 11 websites of state or local government agencies and 61 websites of pertinent professional organizations in Italy.
We used a standardized set of selection criteria to identify potentially relevant publications. The identified documents were assessed for pertinence according to shared criteria established by a selected group of 4 members of the expert panel to select guidelines that fit the objectives of the project.
Only documents containing recommendations for clinical practice were included. Reviews, technology assessments, commentaries to CPGs, and service documents were ex-cluded. The types of biomarker considered were circulating biomarkers measured in body fluids (blood derivatives of serum or plasma/urine) with commercially available assay methods. Fecal blood tests, laboratory tests aimed at monitoring metabolism, organ damage and blood cell counts were not considered, as these do not present a direct relationship with the tumor. Circulating tumor cells, cell-free circulating DNA, and microRNA were also excluded from the assessment. Guidance papers limited to rare tumors, sarcomas, hematological malignancies, the pediatric population, pregnant women, and specific aspects of specialized topics (i.e., imaging techniques, radiotherapy procedures, drug administration modalities) were excluded. We did not consider health care procedures established by the Italian National Health Service at the national and regional level (i.e., hereditary tumors other than those of the ovary and thyroid), nor did we consider screening programs currently provided by the Italian National Health Service (i.e., screening for colorectal cancer, uterine cervix cancer and breast cancer), as the latter do not include circulating TMs. Details on the search strategy and selection criteria will be described in a dedicated report on the systematic review process (in preparation and available from the corresponding author of the present article).
Selection of CPGs was independently performed by 3 examiners on the basis of the titles and abstracts of the 8,266 identified documents. A guidance document was considered potentially relevant when 2 of the 3 examiners opted for inclusion. Documents included by a single examiner were discussed until consensus for inclusion or exclusion was reached.
A total of 1,181 potentially relevant documents were selected, for which full-text reports were obtained. The resulting set was then screened for inclusion and the included reports were grouped by guideline, allowing multiple reports on a single guideline. If several versions of a specific guideline were found, we included the most recently updated version.
We included a final set of 559 CPGs concerning 20 different malignancies: carcinomas of the breast, biliary tract, colon-rectum, endometrium, esophagus, head and neck, kidney, liver, lung, stomach, ovary, pancreas, prostate, uterine cervix, urinary bladder, differentiated and medullary thyroid cancer, germ cell testicular cancer, melanoma, mesothelioma and neuroendocrine tumors.
Quality appraisal of guidelines
The selected guidance documents were further appraised to determine their adherence to the IOM standards, which require CPGs to be based on systematic reviews of existing evidence (1) . The 559 guidance documents were clustered into 2 groups: 127 documents in which systematic reviews were essential to generate recommendations (CPGs) and 432 guidance documents without evidence of systematic review methodology (other guidance documents -OGDs). However, authoritative institutions or medical societies typically produce guidance documents without applying systematic review methods. We also knew up front that these documents are currently used by clinicians in their daily practice. The Steering Committee therefore decided to provide all guidance documents to the panel members with a request to judge which of the OGDs were used by our target audience. Whenever 25% or more of the panel members declared that a given guidance document was used in clinical practice, the guidance document was retained. In all, 111 of 432 OGDs qualified for inclusion.
The development process
The detailed process of document development was agreed upon by the Steering Committee and the Scientific Committee (report in preparation and available from the corresponding author of the present article). The basic steps in the process are summarized below: -classifying the clinical questions (e.g., screening, diagnosis, therapy) -choosing the biomarkers of interest -developing the specific queries on TM use within the clinical questions -retrieving and tagging information concerning every clinical question -data extraction from both types of guidance documents, with quality assessment of CPGs and assessment of clinical use of OGDs -clustering and synthesizing information at decreasing levels of complexity -final write-up.
Classifying the clinical question
Given that the role of TMs may differ widely in the different clinical phases of the disease, we decided to consider the clinical questions separately: (i) screening, (ii) differential diagnosis, (iii) preoperative workup, (iv) reassessment after curative treatment, (v) early detection of recurrence or progression, and (ii) monitoring of treatment response in advanced disease. Details of the considered clinical questions are reported elsewhere (in preparation and available from the corresponding author of the present article).
Developing specific queries within the clinical questions
The information related to the following specific queries were found in the selected guidance documents: 1. Is the use of TM(s) explicitly recommended or not recommended? 2. Which TM(s) is/are recommended or not recommended? 3. In which type of patients is/are TM(s) recommended or not recommended? 4. Can TM(s) be used autonomously or should they be used in association with other tests? 5. Are rules to interpret the result of TM determination provided? 6. Do the TM results have an impact on treatment decisions or, more broadly, on the clinical management of the patient? 7. Is information on possible causes of false positive and false negative results provided? 8. Is information on preanalytical or analytical issues that can influence the reliability of the TM result provided?
Retrieving and tagging information concerning every clinical question
For every malignancy, all information concerning TMs in the different clinical questions was identified in the selected guidance documents. For each guidance document, the relevant information was tagged, extracted (whenever possible as a verbatim transcription) and classified as follows: -Recommendation: part of text explicitly defined and clearly recognizable as recommendation -Supplementary information: (i) implicit advice for clinical practice not recognizable as explicit recommendation; (ii) additional information concerning the application and interpretation of TMs -Supporting evidence: reporting and conclusions of the evidence used by the author team that developed the published guidance document to draw up recommendations.
All information extracted from guidance documents was clustered and synthesized in 4 rounds (levels) of increasing simplification as described elsewhere (report in preparation and available from the corresponding author of the present article) and briefly summarized below. -Level 1: The parts pertaining to TMs were retrieved from every guidance document and transcribed verbatim, preserving the textual structure -e.g., paragraph, complete clause -in which they were included, in a Master table (first-level tabulation) -Level 2: Portions of text strictly referring to TMs were extracted, clustered as recommendations and supplementary information, and transcribed verbatim in a table (secondlevel tabulation). Information from different guidelines was summarized separately -Level 3: Similar recommendations and supplementary information from different guidelines were summarized as a single entry, followed by the acronyms of the CPGs and/ or ODGs formulating them (third-level tabulation: Detailed Summary Table) -Level 4: Essential information to support decision-making in clinical practice was distilled and summarized in a further simplified table (fourth-level tabulation: Take-Home Message).
The present article reports the Detailed Summary Tables and Take-Home Messages, which represent the levels of synthesis suitable for practical use.
Managing information of CPGs and OGDs
Recommendations provided by CPGs are displayed in Detailed Summary Tables and Take-Home Messages. Recommendations from OGDs are embedded in both tables whenever they were consistent with those of CPGs. Recommendations reported exclusively by OGDs are not included in the Take-Home Messages, but are provided as supplementary information in the Detailed Summary Tables. CPGs and OGDs are labeled as such in all tables in order to allow the reader to track the source of the reported information.
Wording
The terms used to formulate recommendations were found to be highly heterogeneous among the included guidelines, reflecting (i) the variable quality of the supporting evidence, (ii) the different weight given to the trade-off between the benefits and harms of an intervention in different contexts, and (iii) the uneven methodological rigor used to develop the guidance documents. In agreement with the scope of the project, the Scientific Committee settled on maintaining the original terms used by different CPGs, thus avoiding any attempt towards harmonization of the terms. When the same recommendation was provided by more than one CPG, the less stringent term (e.g., should rather than have to) was chosen in the synthesis.
Indications concerning TMs can be grouped into 3 categories: positive recommendation (CPG recommends to use TM), negative recommendation (CPG recommends not to use the marker), and no explicit recommendation available. The third category (no explicit recommendation available) encompasses different circumstances in relation to either the availability and quality of evidence or the assessment of benefit and harms, or both.
The following sentences were used in the synthesis to represent the different circumstances in which no recommendations were provided: 1. Clinical question considered, but TMs not addressed: The clinical question (screening, differential diagnosis, initial workup, etc.) is comprehensively considered by the CPG, but circulating TMs are not mentioned.
Clinical question considered, no explicit recommendations
on TMs provided: TMs are mentioned and discussed with reference to the clinical question, but the panel that developed the CPG deemed the available evidence or the assessment of benefit and harms, or both, not adequate to support a positive or negative recommendation. 3. Clinical question considered, but criteria to monitor treatment response (including TMs) not addressed: Response rates to different therapeutic regimens and survival benefits are the most frequently addressed topics by guidance documents in the clinical question "Monitoring of treatment response in advanced disease". If the guidance document does not mention criteria to monitor the response, it cannot be assumed that a systematic search of the primary literature on TMs in this setting was performed. Therefore, a sentence different from the first one was used since it could not be appraised whether the clinical question had been comprehensively considered.
These 3 sentences are used in the Detailed Summary Tables to provide comprehensive information on how different guidelines considered TMs in different clinical questions. In the Take-Home Messages a more general sentence indicating that there are no recommendations on TMs was preferred (Recommendations on TMs not available), given the practical purpose of this level of synthesis. 
Agreeing on the synthesis process and results
The process of synthesis was agreed upon within the Scientific Committee. The Detailed Summary Tables and Take-Home Messages were submitted to the expert panel for evaluation (internal evaluation) and approval of the synthesis, or for suggestions. Comments and suggestions were discussed and accepted when appropriate. The Detailed Summary Tables and Take-Home Messages were then submitted to the members of the Interregional Biomarkers Working Group, instituted by the Health Commission of the Italian Permanent Conference for Relations between State, Regions and the Autonomous Provinces of Trento and Bolzano for external and independent verification of the correctness and completeness of the information summarized in the tables.
Assessment of CPGs with the AGREE II instrument
CPGs were assessed with the Appraisal of Guidelines for Research & Evaluation (AGREE II) tool, in order to facilitate comparison of the quality of the summarized CPGs on the basis of an objective, standardized method (3). The instrument comprises 23 key items organized into 6 domains. Each domain captures a distinct dimension of guideline quality: 1. Scope and purpose; 2. Stakeholder involvement; 3. Rigor of development; 4. Clarity of presentation; 5. Applicability; 6. Editorial independence. An AGREE quality score is calculated for each of the 6 AGREE domains using a 7-point scoring system. A higher score indicates a better quality of the domain. The 6 domain scores are independent and should not be combined into a single score.
Each CPG was rated by 2 evaluators independently. If the CPG addressed multiple diseases, the evaluators considered the documents as many times as the number of diseases addressed. The evaluators achieved high interrater reliability. The scores of the 6 domains were subdivided into quartiles and marked in different colors for easier comprehension of the score (4).
AGREE evaluation
CPGs concerning every malignancy were also assessed with the Appraisal of Guidelines for Research & Evaluation (AGREE II) tool. A higher score equals a better quality of the domain. The results are reported after the Take-Home Message tables. 
Take-home messages
Users' instructions Definition and target audience
Take-Home Messages are presented in table format for every tumor type, summarizing essential information to support decision-making in clinical practice. They are intended for use by health care providers.
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TAKE--HOME MESSAGES --Users' instructions Definition and target audience
Take--Home Messages are presented in table format for every tumor type, summarizing essential information to support decision--making in clinical practice. They are intended for use by health care providers. 
Monitoring of treatment response in advanced disease
Recommendations on TMs not available
CPG/total CPG:
CPGs reporting the summarized information/total number of CPGs that consider the clinical question.
OGD/total OGD: OGDs reporting the summarized information/total number of OGDs that consider the clinical question. 
Monitoring of treatment response in advanced disease
Recommendations on TMs not available 
CPG/total CPG:
CPG/total CPG: CPGs reporting the summarized information/total number of CPGs that consider the clinical question.
OGD/total OGD: OGDs reporting the summarized information/total number of OGDs that consider the clinical question.
∅
The examined CPGs that consider the clinical question either do not address TMs or, if TMs are addressed, CPGs do not present explicit recommendations.
PANCREATIC CANCER
Take-home message
Examined documents: 7 (4 CPGs, 3 OGDs)
Acronyms of CPGs
Domain 1
Scope and purpose 
Detailed summary tables
Users' instructions Definition and target audience
STRUCTURE Total number of selected documents (number of CPGs, number of OGDs)
Biliary cancer Examined documents: 7 (2 CPGs, 5 OGDs)
Clinical question CPG OGD Summary of recommendations (1) Supplementary information (2) Screening of people at increased risk The current evidence does not support routine screening for cholangiocarcinoma in asymptomatic patients with underlying primary sclerosing cholangitis (ACG 2014,
Patients with primary sclerosing cholangitis should undergo careful surveillance for cholangiocarcinoma development mainly during the first 2 years of follow--up (SIGE 2010)
Surveillance with CA19.9 and one imaging technique (CT or MRI) is at present the suggested approach (SIGE
2010)
No study has demonstrated any value for the serum CA19.9 test as a screening modality in asymptomatic primary sclerosing cholangitis (AASLD 2010, SIGE 2010) No primary care evidence was identified pertaining to the diagnostic accuracy of … CA19.9 in patients with suspected gallbladder cancer where the clinical responsibility was retained by primary care (NICE 2015) CA19.9 can be elevated in patients with diseases other than biliary cancer (AASLD 2010, AIRO 2012, NCCN 2015):
Differential diagnosis
--other malignancies (e.g., gastric or pancreatic cancer) --benign conditions (bacterial cholangitis, cholestatic jaundice, gallbladder lithiasis) Patients negative for the Lewis antigen will not have an elevated serum CA19.9 level despite having cholangiocarcinoma (AASLD 2010) Clinical question considered, but TMs not addressed (ESMO 2011) Clinical question CPG OGD Summary of recommendations (1) Supplementary information (2) Monitoring of treatment response in advanced disease 
Recommendations from CPGs and from OGDs, if consistent with those of CPGs. (2) Supplementary information from both CPGs and OGDs, and recommendations from OGDs that are inconsistent with those of CPGs. 
COLORECTAL CANCER
Detailed summary tables
ESOPHAGEAL CANCER
Detailed summary tables
Recommendations from CPGs and from OGDs, if consistent with those of CPGs. (2) Supplementary information from both CPGs and OGDs, and recommendations from OGDs that are inconsistent with those of CPGs. (1) Supplementary information (2) Screening of people at increased risk --every 6--12 months (NCCN 2015) Elevated AFP found during surveillance is not necessary related to cancer (MCC 2011) AFP can also be elevated in intrahepatic cholangiocarcinoma and in some cases of metastasis from colon cancer (NCCN 2015) Differential diagnosis AFP measurement should not be considered a diagnostic test for HCC in the assessment of focal liver lesions (AISF 2013) No primary care evidence was identified pertaining to the diagnostic accuracy of ultrasound, CT, MRI or AFP in patients with suspected liver cancer where the clinical responsibility was retained by primary care (NICE 2015) AFP has low diagnostic sensitivity and specificity (AIOM 2015 , AISF 2013 , NCCN 2015 AFP may also be elevated in intrahepatic cholangiocarcinoma, some metastases from colon cancer, and germ cell tumors (AIOM 2015 , AISF 2013 , NCCN 2015 HEPATOCELLULAR CARCINOMA (HCC) AFP cannot be used to guide therapeutic decisions based on the best scientific evidence currently available (AISF 2013) Clinical question considered, no explicit recommendations on TMs provided (EASL--EORTC 2012, NCCN 2015) (1) Recommendations from CPGs and from OGDs, if consistent with those of CPGs. (2) Supplementary information from both CPGs and OGDs, and recommendations from OGDs that are inconsistent with those of CPGs.
GASTRIC CANCER
Detailed summary tables
Clinical question CPG OGD Summary of recommendations
Detailed summary tables
Liver transplant priority and delisting policies
HEPATOCELLULAR CARCINOMA (HCC)
Detailed summary tables No primary care evidence was identified pertaining to the diagnostic accuracy of TMs (CA19.9 and CA72--4) in patients with suspected pancreatic cancer where the clinical responsibility was retained by primary care (NICE 2015) Serum TMs (CA19.9, CEA) … are useful only when they are positive. When negative, they do not aid in determining the nature of the suspicious lesion and therefore have little influence on the decision to proceed with exploration/resection or not (ISGPS 2014--A)
CA19.9 is of limited diagnostic value since it is not specific for pancreatic cancer (ESMO 2012) CA19.9 has good diagnostic sensitivity and specificity in symptomatic patients (NCCN 2015) and in those with advanced disease (AIOM 2015) CA19.9 may be falsely positive in cases of biliary obstruction (regardless of etiology) (ISGPS 2014--A, AIOM 2015 , ESMO 2012 , NCCN 2015 and in cases of biliary infection (cholangitis) or inflammation (NCCN 2015) CA19.9 may be undetectable in Lewis antigen--negative patients with pancreatic cancer, who are unable to synthesize CA19.9 (ESMO 2012, NCCN 2015) CA19.9 may be included in standard preoperative diagnostics for patients with borderline resectable pancreatic cancer to assess potential benefits in survival with surgery but not for prediction of resectability (ISGPS 2014--B) Serum CA19.9 level alone is not advocated for determining operability in pancreatic cancer (ISGPS 2014--A) Elevated preoperative CA19.9 has negative prognostic value (ISGPS 2014--B, AIOM 2015 , NCCN 2015 but must be evaluated with caution because the evidence is based on retrospective cohort analyses (ISGPS 2014--B) Elevated preoperative CA19.9 levels correlate with advanced stage (ESMO 2012 , NCCN 2015 including peritoneal carcinosis (S3 2014)
Preoperative workup
CA19.9 may be falsely positive in cases of biliary obstruction (regardless of etiology) and in cases of biliary infection (cholangitis) or inflammation (NCCN 2015) CA19.9 may be undetectable in Lewis antigen--negative patients with pancreatic cancer, who are unable to synthesize CA19.9 (ESMO 2012 , NCCN 2015 Preoperative measurement of CA19.9 is therefore best performed when biliary decompression is complete and bilirubin is normal. If biliary decompression is not performed in a jaundiced patient, CA19.9 levels can be assessed but do not represent an accurate baseline (NCCN 2015) CA19.9 should be measured before surgery (AIOM 2015 , NCCN 2015 PANCREATIC CANCER
Detailed summary tables
to be continued Circulating tumor markers: a guide to their appropriate clinical use e360
